RAPT Therapeutics Inc (RAPT)
1.27
-0.30
(-19.11%)
USD |
NASDAQ |
Nov 14, 16:00
1.27
0.00 (0.00%)
After-Hours: 18:08
RAPT Therapeutics Enterprise Value: -60.04M for Nov. 13, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2024 | -60.04M |
| November 12, 2024 | -54.11M |
| November 11, 2024 | -53.76M |
| November 08, 2024 | -13.97M |
| November 07, 2024 | -6.637M |
| November 06, 2024 | -19.90M |
| November 05, 2024 | -29.32M |
| November 04, 2024 | -35.61M |
| November 01, 2024 | -37.00M |
| October 31, 2024 | -40.84M |
| October 30, 2024 | -38.05M |
| October 29, 2024 | -45.03M |
| October 28, 2024 | -47.47M |
| October 25, 2024 | -48.87M |
| October 24, 2024 | -53.06M |
| October 23, 2024 | -54.80M |
| October 22, 2024 | -52.36M |
| October 21, 2024 | -57.42M |
| October 18, 2024 | -52.36M |
| October 17, 2024 | -55.85M |
| October 16, 2024 | -53.76M |
| October 15, 2024 | -51.66M |
| October 14, 2024 | -47.47M |
| October 11, 2024 | -51.31M |
| October 10, 2024 | -56.55M |
| Date | Value |
|---|---|
| October 09, 2024 | -49.57M |
| October 08, 2024 | -49.22M |
| October 07, 2024 | -49.22M |
| October 04, 2024 | -45.03M |
| October 03, 2024 | -45.38M |
| October 02, 2024 | -36.31M |
| October 01, 2024 | -50.27M |
| September 30, 2024 | -44.68M |
| September 27, 2024 | -46.43M |
| September 26, 2024 | -49.57M |
| September 25, 2024 | -53.41M |
| September 24, 2024 | -53.41M |
| September 23, 2024 | -53.41M |
| September 20, 2024 | -52.36M |
| September 19, 2024 | -47.47M |
| September 18, 2024 | -51.31M |
| September 17, 2024 | -48.52M |
| September 16, 2024 | -49.22M |
| September 13, 2024 | -46.78M |
| September 12, 2024 | -47.47M |
| September 11, 2024 | -47.47M |
| September 10, 2024 | -45.38M |
| September 09, 2024 | -44.68M |
| September 06, 2024 | -50.96M |
| September 05, 2024 | -47.47M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-60.04M
Minimum
Nov 13 2024
999.05M
Maximum
Jan 06 2022
438.70M
Average
441.66M
Median
Enterprise Value Benchmarks
| Biomarin Pharmaceutical Inc | 12.37B |
| Arbutus Biopharma Corp | 563.85M |
| GlycoMimetics Inc | 3.536M |
| FibroGen Inc | 6.924M |
| Cidara Therapeutics Inc | -66.26M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -27.66M |
| Total Expenses (Quarterly) | 29.33M |
| EPS Diluted (Quarterly) | -0.71 |
| Earnings Yield | -246.5% |
| Normalized Earnings Yield | -200.79 |